Please login to the form below
Bedgebury win Levemir account
Bedgebury Communications has been appointed by Novo Nordisk to work on the Levemir UK advertising account
Bedgebury Communications has been appointed by Novo Nordisk to work on the Levemir (insulin detemir [rDNA origin] injection) UK advertising account.
Commenting on the recent win, John Russell, Director at Bedgebury Communications, said: "We are delighted to be working with Novo Nordisk on this exciting brand and are confident that our creativity, strategic capabilities, market insight and unrivalled attitude to service will help us to deliver real value to Levemir."
Bedgebury focuses on offering a results-lead communications service, encompassing strategy development, origination and execution of creative concepts and med-ed programmes designed to address key market opportunities.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- How will the events and exhibitions industry change post-Coronavirus?
- Novartis weathers the COVID-19 storm in Q3, lifts outlook
- Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue
- Researchers say COVID-19 antibody levels have fallen rapidly in the UK
- Exploring the potential of eosinophils
- Eliminating pharmaceutical rebates, is this déjà vu?
- Bayer pays an initial $2bn for gene therapy firm AskBio
PMHub
Attigo (part of the Mednet Group)
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...
Latest intelligence
- Exploring the potential of eosinophils
- GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
- Eliminating pharmaceutical rebates, is this déjà vu?
- By Andrew Parece and Matthew Majewski...
- Patients are ready to embrace decentralised clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Quick links
Infographics
